🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab intravenous, 0.9% Sodium Chloride Injection, Avastin 25 mg/ml concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  2. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  3. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  4. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.

    phase 2 small molecule active

    1 trial

  5. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  6. OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  8. OXALIPLATIN, CISPLATIN, OXALIPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., PEMBROLIZUMAB, CAPECITABINE, TRASTUZUMAB, OXALIPLATIN, Rilvegostomig, CAPECITABINE, FLUOROURACIL, volrustomig, DS-8201a

    AstraZeneca AB

    Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressing gastric, GEJ and esophageal cancer

    phase 2 small molecule active

    1 trial

  9. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  10. OXALIPLATIN, IRINOTECAN, Vectibix 20 mg/ml concentrate for solution for infusion, FOLINIC ACID, CALCIUM LEVOFOLINATE, FLUOROURACIL

    Ningbo Cancer Hospital

    RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method

    phase 2 small molecule active

    1 trial

  11. Olaparib Continuous (28-Day cycle) 300 mg BD.

    AstraZeneca

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  12. Omacetaxine

    Teva Pharma GmbH

    Acute Myelogenous Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

  13. Orelabrutinib

    The First People's Hospital of Lianyungang

    Primary Central Nervous System Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  14. Oxaliplatin

    Universal Integrated

    Previously Treated Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  16. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  17. PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Erbitux 5 mg/mL solution for infusion, CARBOPLATINE HOSPIRA 10 mg/ml, solution injectable pour perfusion

    Ningbo Cancer Hospital

    Head and neck squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  18. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, CISPLATIN

    Fondazione Telethon ETS

    Patients with non-metastatic muscle invasive bladder cancer

    phase 2 small molecule active

    1 trial

  19. PACLITAXEL ALBUMIN-BOUND, NIVOLUMAB, GEMCITABINE, IPILIMUMAB, SOTORASIB, ODM-212 5 mg coated tablet, ODM-212 40 mg coated tablet

    Orion Laboratories Pty.

    Neoplasms benign malignant and unspecified (incl. cysts and polyps)

    phase 2 small molecule active

    1 trial

  20. PACLITAXEL ALBUMIN-BOUND, PACLITAXEL , DOCETAXEL , Placebo to V940, KEYTRUDA 25 mg/mL concentrate for solution for infusion., mRNA-4157, CARBOPLATIN

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  21. PACLITAXEL, Durvalumab_IJB, CARBOPLATIN, Oleclumab_IJB

    The George Institute

    Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

    phase 2 small molecule active

    1 trial

  22. PACLITAXEL, MYCOPHENOLATE MOFETIL, volrustomig, INFLIXIMAB, FLUOROURACIL, CISPLATIN

    AstraZeneca AB

    Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).

    phase 2 small molecule active

    1 trial

  23. PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  24. PAXALISIB

    KAZIA THERAPEUTICS LTD

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources